This is a summary of the European public assessment report (EPAR) for Granupas. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Granupas. For practical information about using Granupas, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
N/AATC Code
J04AA01
ATC Item
4-aminosalicylic acid
Pharmacotherapeutic Group
Antimycobacterials
Active Substance (Summary)
INN / Common Names
N/AEMA Name
Granupas (previously Para-aminosalicylic acid Lucane)
Medicine Name
Granupas (previously Para-aminosalicylic acid Lucane)
Aliases
N/ANo risk management plan link.
